Coronary bypass grafting using crossclamp fibrillation does not result in reliable reperfusion of the myocardium when the crossclamp is intermittently released: a prospective cohort study

Joel Dunning*, Steven Hunter, Simon WH Kendall, John Wallis and W Andrew Owens

Address: Department of Cardiothoracic Surgery, James Cook University Hospital, Middlesbrough, UK
Email: Joel Dunning* - joeldunning@doctors.org.uk; Steven Hunter - Steve.Hunter@stees.nhs.uk; Simon WH Kendall - Simon.Kendall@stees.nhs.uk; John Wallis - John.Wallis@stees.nhs.uk; W Andrew Owens - Andrew.Owens@stees.nhs.uk
* Corresponding author

Abstract

**Background:** Cross-clamp fibrillation is a well established method of performing coronary grafting, but its clinical effect on the myocardium is unknown. We sought to measure these effects clinically using the Khuri Intramyocardial pH monitor.

**Methods:** 50 episodes of cross-clamping were recorded in 16 patients who underwent CABG with crossclamp-fibrillation. An Intramyocardial pH probe measured the level of acidosis in the anterior and posterior myocardium in real-time. The pH at the start and end of each period of crossclamping was recorded.

**Results:** It became very apparent that the pH of some patients recovered quickly while others entirely failed to recover. Thus the patients were split into 2 groups according to whether the pH recovered to above 6.8 after the first crossclamp-release (N = 8 in each group). Initial pH was 7.133 (range 6.974–7.239). After the first period of crossclamping the pH dropped to 6.381 (range 6.034–6.684). The pH in recoverers prior to the second XC application was 6.990 (range 6.808–7.222) compared to only 6.455 (range 6.200–6.737) in patients whose myocardium did not recover (P < 0.0005). This finding was repeated after the second XC release (mean pH 7.005 vs 6.537) and the third (mean pH 6.736 vs 6.376). However prior to separation from bypass the pH was close to the initial pH in both groups (7.062 vs 7.038).

**Conclusion:** Crossclamp fibrillation does not result in reliable reperfusion of the myocardium between periods of crossclamping.

Background

Cross Clamp fibrillation is a well established technique for performing Coronary Bypass Grafting and it is routinely used by 15% of surgeons in the UK [1-3] Proponents of this technique report that this method subjects the heart to only short periods of ischaemia, with full reperfusion after every distal anastomosis. In addition the possibility that ischaemic preconditioning occurs as subsequent grafts are performed is proposed to further protect the myocardium [4-6]. It is commonly thought that...
ischaemic periods of up to 10–15 minutes are easily tolerated by the myocardium and clinical practise would suggest that cross-clamp fibrillation has identical outcomes to coronary bypass surgery using cardioplegia. However no study has yet been performed that has demonstrated adequate reperfusion between periods of cross clamp fibrillation and the phenomenon of ischaemic preconditioning has not yet been clinically demonstrated during cardiac surgery.

The Khuri Myocardial pH monitor has been recently developed that can for the first time provide real-time clinical analysis of the myocardial pH during cardiopulmonary bypass [7-10]. It has been well validated during cardiopulmonary bypass with cardioplegia in over 500 clinical cases and periods of low intramyocardial pH have been correlated with increased myocardial damage [11].

We sought to investigate the effect of cross-clamp fibrillation on the pH of the myocardium with the primary hypothesis that we may be able to define a 'safe-ischaemic time' for cross-clamping, and a secondary hypothesis that we may be able to measure ischaemic preconditioning in clinical practise for the first time.

Methods

16 patients undergoing elective coronary bypass grafting using cross-clamp fibrillation had a Khuri intramyocardial pH monitor placed intra-operatively. The monitor consists of two probes. The first (anterior) probe is placed prior to cardiopulmonary bypass into the left ventricle, lateral to the LAD, directed obliquely into the anterior ventricular septum. The second probe is placed lateral to the posterior descending artery, again in an oblique fashion so that the tip rests in the posterior portion of the ventricular septum. Continuous pH monitoring is then performed with pH measurements recorded every 10 seconds. Cardiopulmonary bypass was performed at 37 degrees centigrade, but the pH probe also contains a temperature probe and provides a pH value corrected to normothermia.

Operative technique was not modified in any way for this study. The PDA or RCA was first grafted with the cross clamp applied for the distal anastomosis and released as the proximal anastomosis is formed. Lateral wall grafts were then performed, with the LAD being the last graft to be placed. The maximal pH recovery was determined as the pH just before the subsequent cross clamp placement. The posterior probe was removed prior to separation from bypass but the anterior probe remained in place until separation from bypass and a constant final pH reading was achieved.

Results

20 patients were entered into the study but 3 patients had malpositioning of the pH probe and puncture of the left ventricle causing misreading, and in a 4th patient the probe was opened but not used. The remaining 16 patients had 50 periods of crossclamping to fashion 47 distal anastomoses. The demographics of these patients are shown in table 1. When the traces were analysed, it became clear that the pH recovered well on release of the crossclamp for some patients, but in other patients there was a complete failure to recover (See figures 1 and 2). We therefore split the data into two groups as well as analysing the traces as a whole. The full results of the analysis are shown in table 2.

The initial pH was 7.133 (range 6.974–7.239) for the group as a whole. On cross-clamping the pH reduced, with mean pH after the first cross-clamp removal being 6.381 (SD 0.165 and range 6.034–6.684). The recovery after cross clamp removal was highly inconsistent. The mean pH at the end of the first period of cross clamp release was 6.723 (SD 0.324), but in patients we termed as non-recoverers the mean pH rose to only 6.455 (SD 0.067) compared to recoverers whose pH rose to 6.990 (SD 0.561). These findings were repeated for subsequent applications of the cross-clamp. However at the end of the period of pH measurement (Once off bypass) there was no significant difference in myocardial pH between these two groups [7.062 (SD 0.0945) in recoverers and 7.038 (SD 0.258) in the non-recoverers (p = 0.810)].

We further subanalysed the rate of descent of the pH in the 8 patients who did have acceptable recovery of the pH on cross clamp removal. We found that the rate of descent after the first cross clamp was 0.355 in 5 minutes, the rate of descent after the second cross clamp was 0.186 in 5 minutes and the rate of descent after the third cross clamp

Statistical analysis

The pH recordings were analysed and the pH recordings prior to, 5 minutes into and after cross clamping were recorded. The average values of the anterior and the posterior probe recordings were taken. In addition the maximum pH recovery after crossclamp removal was documented (which was recorded only by the anterior probe). 2 groups were retrospectively defined according to whether the pH recovered to above 6.8. The cut-off point of 6.8 was determined purely by an observational assessment and the conclusion that patients whose pH did not recover to above this level seemed to be different to those that did. The 2 groups were created simply to highlight this observational difference. The pH values were compared between these groups using the unpaired Student t-test, after normality was established using the Kolmogorov-Smirnov test.
was 0.0152 in 5 minutes. This was a significant reduction in the rate of descent in pH as the number of periods of cross-clamping increased (p = 0.009). The clinical outcomes for the 16 patients are shown in table 3.

### Discussion

To our knowledge this is the first study to investigate the level of ischaemia found in the myocardium during coronary arterial bypass grafting using the technique of cross-clamp fibrillation. We have documented for the steady reduction in pH during this technique, which reaches pH levels as low as 6.03, and on average the pH dropped to 6.38 prior to first cross clamp removal.

We have also documented for the first time 8 patients whose intramyocardial pH did not recover once the cross clamp was removed. We hypothesise that the reason for this lack of recovery is that despite removal of the cross-clamp, blood did not perfuse the native coronary arteries (or the graft after second cross clamp removal). The reasons for this lack of perfusion require further research but possibilities would include the much lower aortic root pressure than the physiological situation (or the pressure that cardioplegia is given in patients undergoing cardiopelgic techniques) and changes in the resistance of heavily diseased vessels that may now be twisted or compressed.

One further interesting preliminary finding is that in those patients who do undergo ischaemia and then recovery, the rate of descent of the pH reduced significantly on subsequent cross clamp applications. To our knowledge this is the first demonstration in the clinical situation that ischaemic preconditioning has been shown. This clinical demonstration confirms a large number of animal studies performed up to 20 years ago that clearly show the existence of ischaemic preconditioning [12-15].

Our study has many weaknesses due to its preliminary nature. The splitting of our patients into 2 groups was entirely retrospective in nature and was done in order to understand further the results we were seeing for the first time. However while we felt that the two groups behaved very differently, there may in fact be a spectrum of patients rather than two distinct groups. This requires further patients to undergo intramyocardial pH monitoring during cross-clamp fibrillation. Secondly our initial report of ischaemic preconditioning is based on only 8 patients and this requires many more patients to establish that this is a physiological phenomenon in everyday clinical practise.

It has been clearly and repeatedly demonstrated in well-conducted prospective randomized trials that the technique of cross clamp fibrillation is equivalent to both crystalloid and blood cardioplegia in terms of clinical outcome and biochemical markers of myocardial damage [16-22]. In 1998 Liu et al[17] compared the results of 1,345 patients who had cross-clamp fibrillation with 578 patients who had coronary arterial bypass grafts with cold crystalloid cardioplegia at one institution during the same time period. The groups had identical mortality, stroke rates, ICU stay, haemofiltration rates and re sternotomy rates. Alhan et al[20] compared 128 patients having CABG with cold crystalloid cardioplegia with 271 patients having CABG with crossclamp fibrillation, and found no differences in clinical outcomes, including mortality,
IABP use, inotropic requirements and myocardial infarction. Gerola et al[22] performed a prospective randomized trial of 60 patients randomized to either aspartate-glutamate enriched warm blood cardioplegia or cross clamp fibrillation. Again there were no differences in mortality, cardiac index, or myocardial infarction rates. Finally, in a prospective randomized trial, Musumeci et al[18] randomized 43 patients to cross clamp fibrillation and 48 to cold blood cardioplegia. Levels of CK, MB, S-100B, Troponin I and T, LV function, ECG changes and number of cerebral micro-emboli were either similar between the two groups or superior in the crossclamp fibrillation group.

Thus clinically and biochemically cross clamp fibrillation is indistinguishable from cardioplegic techniques. In contrast Khuri et al have performed over 500 measurements of intamycocardial pH during cardiac surgery using cardioplegia. He has correlated a pH of below 6.87 at the end of bypass with an increase in inotrope requirement[7] and a pH of below 6.34 during crossclamping with an increase in long term mortality[8,9]. In addition he has found that the level of apoptosis in samples of myocardium exposed to a pH of 6.34 was three times higher than tissue at normal pH[11].

We have established that the pH of the myocardium routinely falls to very low levels during cross clamp fibrillation. However repeated studies have shown equivalence between cross clamp fibrillation and cardioplegic techniques. Thus it is possible that Khuri’s findings of poorer short and long term outcomes with lower pH levels in patients having surgery using cardioplegia would not extrapolate to patients having periods of profound myocardial acidosis during cross clamp fibrillation.

Our preliminary study cannot answer whether ischemic preconditioning accounts for the heart’s ability to sustain this profound ischemia during cross clamp fibrillation and indeed our finding of several patients who had sus-
Figure 2
An example of a patient with successful reperfusion (Top light line) and a patient with unsuccessful reperfusion (lower heavy line). The arrows represent application and release of the crossclamp. Of note the patient that did not have recovery received a RIMA graft as the second anastomosis.

Table 2: Results of pH analysis with Khuri Intramyocardial pH probe

|                  | Total pH          | Recoverers       | non recoverers  | p value |
|------------------|-------------------|------------------|-----------------|---------|
| Initial pH       | 7.133 (SD 0.0625) | 7.132 (SD 0.0121)| 7.134 (SD 0.0305)| 0.958   |
| pH after 1st XC  | 6.381 (SD 0.165)  | 6.445 (SD 0.126) | 6.317 (SD 0.183) | 0.124   |
| pH Recovery after 1st XC | 6.723 (SD 0.324) | 6.990 (SD 0.561) | 6.455 (SD 0.067) | <0.0005 |
| pH after 2nd XC  | 6.495 (SD 0.192)  | 6.610 (SD 0.131) | 6.381 (SD 0.180) | 0.012   |
| pH Recovery after 2nd XC | 6.769 (SD 0.303) | 7.005 (SD 0.1193)| 6.537 (SD 0.240) | <0.0005 |
| pH after 3rd XC  | 6.530 (SD 0.267)  | 6.736 (SD 0.159) | 6.376 (SD 0.224) | 0.006   |
| pH Recovery after 3rd XC | 6.919 (SD 0.304) | 7.081 (SD 0.0838)| 6.798 (SD 0.356) | 0.084   |
| Final pH         | 7.050 (SD 0.188)  | 7.062 (SD 0.0945)| 7.038 (SD 0.258) | 0.810   |
| pH drop for each period of cross clamping |                   |                  |                 |         |
| Drop in 5 mins 1st XC | 0.355 (SD 0.0690) | 0.320 (SD 0.165) |                 |         |
| Drop in 5 mins 2nd XC | 0.186 (SD 0.175)  | 0.0742 (SD 0.0708)|                 |         |
| Drop in 5 mins 3rd XC | 0.152 (SD 0.0696) | 0.103 (SD 0.119) |                 |         |
| P value          |                   |                  |                 | 0.009   |
tained ischaemia suggest that the mechanisms by which the myocardium is protected from apoptosis remain unknown.

We suggest that further studies of patients undergoing crossclamp fibrillation are performed in order to further elucidate the factors that allow adequate reperfusion and also to investigate the clinical phenomenon of ischaemic preconditioning. Furthermore we were unable to determine a 'safe-period' for crossclamp application due to the intermittent nature of reperfusion. Once further studies are performed to elucidate the conditions for reliable reperfusion, a 'safe-ischaemic time' may become possible to determine.

**Conclusion**

Crossclamp fibrillation does not result in reliable reperfusion of the myocardium between periods of crossclamping.

**Abbreviations**

| Abbreviation | Description |
|--------------|-------------|
| LIMA         | Left Internal Mammary Artery |
| BIMA         | Bilateral Internal Mammary Arteries |
| CK-MB        | Creatinine Kinase-Myocardial Band |
| SD           | Standard Deviation |
| PDA          | Posterior Descending Artery |
| RCA          | Right Coronary Artery |
| LAD          | Left Anterior Descending Artery |
| LMS          | Left Main Stem Coronary Artery |
| UK           | United Kingdom |
| CABG         | Coronary Arterial Bypass Grafts |
| BMI          | Body Mass Index |
| XC           | Cross Clamp |

**EF:** Ejection Fraction  
**MI:** Myocardial Infarction  
**CICU:** Cardiothoracic Intensive Care Unit

**Competing interests**

The author(s) declare that they have no competing interests.

**References**

1. Karthik S, Grayson AD, Oo AY, Fabri BM: A survey of current myocardial protection practices during coronary artery bypass grafting. Ann R Coll Surg Engl 2004, 86:413-415.
2. Bonchek LI, Burlingame MW, Vazquez BE, Lundy EF, Gassmann CJ: Applicability of noncardioplegic coronary bypass to high-risk patients. J Thorac Cardiovasc Surg 1992, 103:230-237.
3. Raco L, Mills E, Milliner RJ: Isolated myocardial revascularization with intermittent aortic cross-clamping: experience with 800 cases. Ann Thorac Surg 2005, 73:1436-1440.
4. Marber M, Walker D, Yellon D: Ischaemic preconditioning (Editorial). BMJ 1994, 301:1-2.
5. Abd-Elfattah AS, Ding M, Wechsler AS: Intermittent aortic cross-clamping prevents cumulative adenosine triphosphate depletion, ventricular fibrillation, and dysfunction (Stunning) - Is it preconditioning? J Thorac Cardiovasc Surg 1995, 110:328-339.
6. Yellon DM, Alkhulaifi AM, Pugleby WB: Preconditioning the human myocardium. Lancet 1993, 342:276-277.
7. Kumbhani DJ, Healey NA, Birjiniuk V, Crittenden MD, Trenor PR, Al Tabbaa AK, Khuri SF: Intraoperative regional myocardial acidosis predicts the need for inotropic support in cardiac surgery. American Journal of Surgery 188(5):474-80, 2004.
8. Kumbhani DJ, Healey NA, Birjiniuk V, Crittenden MD, Josa M, Trenor PR, Khuri SF: Determinants of regional myocardial acidosis during cardiac surgery. Surgery 136(2):190-8, 2004.
9. Khuri SF, Healey NA, Hossain M, Birjiniuk V, Crittenden MD, Josa M, Trenor PR, Najjar SF, Kumbhani DJ, Henderson W: Intraoperative regional myocardial acidosis and reduction in long-term survival after cardiac surgery. J Thorac Cardiovasc Surg 2005, 129:372-381.
10. Dearani JA, Axford TC, Patel MA, Healey NA, Lavin PT, Khuri SF: Role of myocardial temperature measurement in monitoring the adequacy of myocardial protection during cardiac surgery. Annals of Thoracic Surgery 72(6):S2235-43; discussion S2243-4, S2267-70, 2001.
11. Thatte HS, Rhee JH, Zagarins SE, Trenor PR, Birjiniuk V, Crittenden MD, Khuri SF: Acidosis-induced apoptosis in human and porcine heart. Annals of Thoracic Surgery 77(4):1376-83, 2004.
12. Hillis LD, Khuri SF, Braunwald E, Kloner RA, Tow D, Barsamian EM, Maroko PR: The mass spectrometric measurement of intramural carbon dioxide tension to assess the efficacy of interventions to limit myocardial ischemic injury. Trans Assoc Am Physic J 1978, 91:259-267.
13. Hillis LD, Khuri SF, Braunwald E, Maroko PR: The role of propranolol's negative chronotrophic effect on protection of the ischemic myocardium. Pharmacology 1979:202-208.

**Table 3: Post-operative results of patients undergoing pH analysis**

|                     | Total (N = 16) | Recoverers (N = 8) | Non Recoverers (N = 8) |
|---------------------|---------------|-------------------|-----------------------|
| Mean CICU Stay (range) | 1.25 (1–3)    | 1.13 (1–2)        | 1.38 (1–3)            |
| Mean Hospital stay (range) | 7.81 (4–17)  | 7.38 (4–14)       | 8.25 (4–17)           |
| Inotrope usage      | 0             | 0                 | 0                     |
| Atrial Fibrillation | 3             | 1                 | 2                     |
| Resternotomy        | 1             | 1                 | 0                     |
14. Rude RE, Kloner RA, Maroko PR, Khuri SF, Karaffa S, DeBoer LW, Braunwald E. Effects of amrinone on experimental acute myocardial ischemic injury. J Cardiovasc Res 1980, 14:419-427.

15. Warner KG, Khuri SF, Marston W, Sharma S, Butler MD, Assousa SN, Saad AJ, Siouff SY, Lavin PT. Significance of the transmural diminution in regional hydrogen ion production after repeated coronary artery occlusions. Circulation Research 64(3):616-28, 1989.

16. Korbmacher B, Simic O, Schulte HD, Sons H, Schipke JD. Intermittent aortic cross-clamping for coronary artery bypass grafting: a review of a safe, fast simple and successful technique. J Cardiovasc Surg (Torino) 2004, 45:535-543.

17. Liu Z, Valenza O, Treasure T, Murday AJ, Liu Z, Valenza O, Treasure T, Murday AJ. Cold blood cardioplegia or intermittent cross-clamping in coronary artery bypass grafting? Ann Thorac Surg 1998, 66:462-465.

18. Musumeci F, Feccia M, MacCarthy PA, Ellis GR, Mammana L, Brinn F, Penny WJ, Musumeci F, Feccia M, MacCarthy PA, Ellis GR, Mammana L, Brinn F, Penny WJ. Prospective randomized trial of single clamp technique versus intermittent ischaemic arrest: myocardial and neurological outcome. Eur J Cardiothorac Surg 1998, 13:702-709.

19. Cohen AS, Hadjinkolaou L, McColl A, Richmond W, Sapsford RA, Glenville BE, Cohen AS, Hadjinkolaou L, McColl A, Richmond W, Sapsford RA, Glenville BE. Lipid peroxidation, antioxidant status and troponin-T following cardiopulmonary bypass. A comparison between intermittent crossclamp with fibrillation and crystalloid cardioplegia. Eur J Cardiothorac Surg 1997, 12:248-253.

20. Alhan HC, Karabulut H, Tosun R, Karakoc F, Okar I, Demiray E, Tarcan S, Yigter B, Alhan HC, Karabulut H, Tosun R, Karakoc F, Okar I, Demiray E, Tarcan S, Yigter B. Intermittent aortic cross-clamping and cold crystalloid cardioplegia for low-risk coronary patients. [see comment]. Ann Thorac Surg 1996, 61:834-839.

21. Anderson JR, Hossein-Nia M, Kallis P, Pye M, Holt DW, Murday AJ, Treasure T, Anderson JR, Hossein-Nia M, Kallis P, Pye M, Holt DW, Murday AJ, Treasure T. Comparison of two strategies for myocardial management during coronary artery operations. [see comment]. Ann Thorac Surg 1994, 58:768-772.

22. Gerola LR, Oliveira SA, Moreira LF, Dallan LA, Delgado P, da Luz PL, Jatene AD, Gerola LR, Oliveira SA, Moreira LF, Dallan LA, Delgado P, da Luz PL, Jatene AD. Blood cardioplegia with warm reperfusion versus intermittent aortic crossclamping in myocardial revascularization. Randomized controlled trial. J Thorac Cardiovasc Surg 1993, 106:491-496.